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Identification of Selective Inhibitors
for the Glycosyltransferase MurG
via High-Throughput Screening
One approach involves making compounds in which
the nucleoside or nucleotide portion of the NDP-sugar
donor is elaborated with other groups, either singly or
in a combinatorial fashion [15, 18, 23, 24]. Since the NDP
portion of the glycosyl donor typically plays a significant
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will provide selectivity for the specific Gtf. Many bisub-
strate analogs fall into this category of potential inhibi-
tors, and some low micromolar (IC50) inhibitors haveSummary
been identified following this approach. The most potent
compounds typically contain an intact NDP group be-Nucleotide-glycosyltransferases (NDP-Gtfs) play key
cause the nucleosides alone usually do not bind veryroles in a wide range of biological processes. It is
well [18, 23, 24]. A drawback of this approach is thatdifficult to probe the roles of individual glycosyltrans-
NDP groups do not have the appropriate characteristicsferases or their products because, with few excep-
for cell penetration, and it is unlikely that NDP-basedtions, selective glycosyltransferase inhibitors do not
Gtf inhibitors will be useful for blocking Gtfs inside cells.exist. Here, we investigate a high-throughput ap-
The second major approach toward Gtf inhibitors usesproach to identify glycosyltransferase inhibitors based
iminocyclitols or related glycosidase inhibitors as scaf-on a fluorescent donor displacement assay. We have
folds [17–19, 25]. Glycosidic bond hydrolysis involvesapplied the screen to E. coli MurG, an enzyme that is
the formation of an oxonium ion-like transition state [26],both a potential antibiotic target and a paradigm for
which is stabilized by carboxylate side chains in thea large family of glycosyltransferases. We show that
enzyme active site. Iminocyclitols are believed to mimicthe compounds identified in the donor-displacement
this transition state. Since the transition state for glyco-screen of MurG are selective for MurG over other en-
syl transfer is also believed to involve a species withzymes that use similar or identical substrates, includ-
oxonium ion-like character [10], iminocyclitols have alsoing structurally related enzymes. The donor displace-
been investigated as Gtf inhibitors. Unfortunately, imino-ment assay described here should be adaptable to
cyclitols and other glycosidase inhibitors have provenmany other NDP-Gtfs and represents a new strategy
to be poor inhibitors of Gtfs [18], perhaps because theto identify selective NDP-Gtf inhibitors.
oxonium-ion-like species in Gtf reactions forms an ion
pair with the nucleotide leaving group instead of with a
Introduction carboxylate group. Consistent with this hypothesis, it
has been found that iminocyclitols that are poor NDP-
MurG is a nucleoside diphospho-glycosyltransferase Gtf inhibitors on their own show synergistic inhibition
(NDP-Gtf) involved in murein biosynthesis. It catalyzes with nucleotides [27]. In any event, glycosidase inhibi-
the transfer of N-acetyl glucosamine (GlcNAc) from tors have not proven to be good starting points for Gtf
UDP-GlcNAc to Lipid I, an N-acetyl muramic acid (Mur- inhibitor design.
NAc) derivative that is anchored to the cytoplasmic sur- An alternative approach to identifying Gtf inhibitors is
face of the bacterial cell membrane [1, 2] (Figure 1). The to screen a purified enzyme against large combinatorial
GlcNAc-MurNAc product of the MurG reaction is the libraries to generate leads that can be optimized. Al-
minimal subunit of the peptidoglycan polymer that sur- though Gtfs have been screened against small biased
rounds and protects bacterial cell membranes. Because libraries, high-throughput screening of Gtfs is still in its
peptidoglycan is required for the survival of bacterial infancy [28, 29]. Recently, we reported a strategy for
cells, all of the enzymes involved in its biosynthesis are high-throughput screening of E. coli MurG that involves
targets for new antibiotics [3]. We have recently become displacement of a fluorescently labeled UDP-GlcNAc
interested in strategies to identify inhibitors of MurG derivative from the glycosyl donor binding site [30]. We
for two reasons [4–8]. First, biologically active MurG have suggested that this screening strategy can be
inhibitors would represent a novel class of antibiotics readily adapted to screen many other Gtfs. Herein, we
with which to combat resistant bacterial strains. Sec- describe the rationale underlying this strategy, and we
ond, MurG is a prototypical member of a large but poorly address a key issue: whether a screen based upon dis-
understood class of enzymes, the NDP-Gtfs, which play placement of an ubiquitous cellular substrate such as
key roles in eukaryotic and prokaryotic cell biology UDP-GlcNAc can possibly yield selective inhibitors. Our
[9–14]. Although the utility of specific inhibitors of indi- initial results suggest that it will be possible to discover
vidual Gtfs as tools with which to probe glycosylation selective Gtf inhibitors using this strategy. The implica-
pathways is widely recognized, the best strategy to de- tions of our findings are discussed.
velop such inhibitors is unclear.
Most approaches to the design of NDP-Gtf inhibitors Results
have typically fallen into two major categories [15–22].
The challenge in any high-throughput screen is to de-
velop a simple, reliable assay that can be adapted to*Correspondence: swalker@princeton.edu
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it reacts more slowly than natural UDP-GlcNAc, F1 was
found to be a substrate for MurG, showing that the
N-acyl group is a suitable position to modify.
We next evaluated the ability of the fluorescent glyco-
syl donor to bind to MurG by titrating a solution of F1 with
the enzyme while monitoring fluorescence polarization.
The polarization increases as MurG is added, indicating
that F1 binds. The data fit well to an equation for 1:1
binding, and we calculated a dissociation constant of
1.40.2M for the interaction. Addition of UDP-GlcNAc
to the MurG:F1 solution causes the polarization to drop,
consistent with competitive displacement of the fluores-
cent donor from the active site [30]. We then tested the
assay on a series of compounds that are known to inhibit
MurG. The binding constant for each inhibitor was deter-
Figure 1. MurG Plays an Essential Role in Peptidoglycan Biosyn- mined from the concentrations required to displace the
thesis fluorescent glycosyl donor; the results correlate with the
MurG, a membrane-associated glycosyltransferase, converts Lipid IC50s determined previously using a kinetic assay [5]
I to Lipid II, which is translocated across the membrane and then (Table 1). These initial experiments validated the dis-
polymerized by the transglycosylases. placement assay and suggested that it would be possi-
ble to discriminate between strong and weak binders
in a high-throughput assay by monitoring changes inscreen large numbers of compounds. We envisioned a
polarization at a single concentration of compound.screen that would be straightforward, technically sim-
ple, and inexpensive. An assay based on displacement
of a fluorescently labeled glycosyl donor fulfilled these Screening
We established a set of conditions (2.6 M MurG, 0.33criteria. E. coli MurG is an ideal model system to use in
developing a donor displacement assay because there M fluorescent ligand concentrations) at which 25 M
UDP caused a 50% drop in fluorescence polarization.is an X-ray structure of the enzyme containing an intact
glycosyl donor molecule [8]. From this crystal structure, UDP was used to standardize conditions because it
binds to MurG with a dissociation constant of 2.6 we can predict how the glycosyl donor can be modified
without disrupting enzyme binding. Our structure shows 0.2 M, and we wanted to select for compounds with
comparable or better affinity. The conditions werethat most of the glycosyl donor is buried in the active
site cleft with numerous contacts to the enzyme (Figure adapted to a 20 l scale, and the screening was carried
out in 384-well microplates. We then screened approxi-2A). However, the methyl group of the N-acetyl moiety
at C2 protrudes from the active site and does not contact mately 64,000 molecules in duplicate at a concentration
of 25 g/ml of each inhibitor (molecular weights of thethe enzyme. The structure suggested that it would be
possible to modify the N-acyl substituent with a fluoro- compounds in the library typically fell into the range of
400–600 g/mol). The molecules screened came from aphore without affecting the interactions of the rest of the
glycosyl donor with the enzyme. Based on our structural variety of different compound libraries, including com-
mercial and diversity-oriented synthesis (DOS) librariesanalysis, we prepared the fluorescently labeled N-acetyl
glucosamino derivative F1 (Figure 2B) and evaluated its (see Experimental Procedures), to ensure that a wide
range of structural diversity was represented in the sam-ability to function as a glycosyl donor for MurG. Although
Figure 2. Design of the Fluorescent Ligand Used for High-Throughput Screening
(A) Crystal structure of the binding pocket of the MurG:UDP-GlcNAc complex.
(B) The probe used in high-throughput screening is shown. For details on the preparation of F1, see Helm et al. [30].
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Table 1. Dissociation Constants of Donor Sugar UDP-GlcNAc and Its Analogs
Compound F1 UDP-GlcNAc UDP-GalNAc UDP UMP ADP
Dissociation constant (M)a 1.8  0.2 1.4  0.2 73.1  14.1 2.6  0.2 99.6  12.2 88.2  26.9
Signal change at 25 M — 60% 10% 50% 10% 10%
a Dissociation constants were measured using the fluorescence polarization displacement assay.
ple set. Compounds that reproducibly caused a 50% or It is worth noting that some of the inhibitors identified
in our displacement screen bear intriguing structuralgreater drop in polarization were scored as hits. Using
this cutoff, we identified 456 hits (0.6% hit rate). A num- similarities to inhibitors that are proposed to compete
with the NDP-sugar substrates of a variety of other en-ber of the compounds in the libraries fluoresce, thereby
causing a change in the polarization unrelated to the zymes [33, 34]. In particular, similar heterocyclic cores
are found in inhibitors of other NDP-sugar processingdisplacement of F1 from the binding site. Therefore, the
actual hit rate is lower than 0.6%. enzymes. We and others have proposed that certain
scaffolds mimic the diphosphate linkages found in theseWe selected 220 compounds from the 456 hits to
evaluate for MurG inhibition in a kinetic assay that moni- NDP-sugar substrates with respect to orienting the
attached substituents toward the nucleoside and hex-tors the incorporation of radioactivity from radiolabeled
UDP-GlcNAc into Lipid II. UDP was again used to stan- ose binding sites [30, 35]. We are attempting to obtain
cocomplexes of MurG with some of the inhibitors bounddardize the secondary assay. Reaction conditions were
chosen wherein a 5 M concentration of UDP caused so that we can evaluate the role of the heterocyclic
cores in binding. If the heterocylic cores do prove toa 50% drop in product formation. Under these reaction
conditions, both the UDP-GlcNAc and Lipid I concentra- function as mimetics of the diphosphate linkage, then
it may be possible to make focused Gtf inhibitor librariestions are within 2-fold of their Km values. Since we
wanted to identify compounds with comparable or bet- by diversifying around a small number of cores.
ter potency than UDP, we evaluated each test com-
pound in duplicate at a concentration of 5 g/ml and Selectivity
An enormous number of enzymes in both eukaryoticscored as positives all those that inhibited MurG by at
least 40%. Fifty-five out of 220 compounds (25%) met and prokaryotic cells utilize UDP-GlcNAc or related nu-
cleotide sugars as substrates. Our screen is based onor exceeded this cutoff, and we measured the IC50 values
for these compounds using the same radiometric assay. displacement of an UDP-GlcNAc derivative, prompting
concerns that the hits obtained will bind to many UDP-In general, the IC50 values of the compounds fell between
1 and 10 M. For some compounds, the IC50 curves hexose processing enzymes. To assess the utility of
the donor displacement assay, we needed to determinerevealed that complete inhibition could not be achieved:
at some critical concentration inhibition decreased sig- whether the inhibitors obtained were selective for MurG
over other enzymes that use similar or identical sub-nificantly. We interpreted this behavior as indicating that
some compounds aggregate at higher concentrations. strates.
MurG is an inverting glycosyltransferase that cata-The aggregation clearly interferes with the ability of
these compounds to inhibit MurG activity. However, lyzes the formation of a  glycosidic linkage from an
-linked UDP-sugar donor [8]. Therefore, we chose tothese same compounds were identified as hits in the
ligand-displacement screen at concentrations above test the hits against two other inverting glycosyltransfer-
ases that also use UDP donors. One of these Gtfs,the critical concentration for aggregation. It has pre-
viously been observed that compound aggregation can O-linked GlcNAc transferase (OGT), is a eukaryotic gly-
cosyltransferase that uses UDP-GlcNAc as a glycosyllead to false positives in kinetic assays [31], but these
results suggest that the phenomenon can also lead to donor [36]. Sequence-based computational studies
have suggested that OGT belongs to the same structuralfalse negatives. The displacement assay is apparently
less sensitive to aggregation-induced artifacts. superfamily as MurG [37]. The other Gtf we tested, GtfB,
is a prokaryotic Gtf involved in the biosynthesis of glyco-An analysis of the screening results revealed that
many of the compounds identified in the secondary peptide antibiotics [38]. Its natural donor is UDP-glu-
cose, and an X-ray structure shows that its structurescreen contain a 1,3-disubstituted heterocyclic core. In
fact, 31 out of the 55 compounds (56%) were found to is remarkably similar to that of MurG [39]. In fact, the
C-terminal domains of MurG and GtfB, which containcontain one of the cores shown in Figure 3 [32]. We
selected a subset of the hits (compounds 1, 5, and 7) the glycosyl donor binding sites, have an rmsd of 0.6 A˚
over all C-terminal C- atoms. In addition to these Gtfs,for further kinetic analysis and found that they were
competitive inhibitors with respect to UDP-GlcNAc (Fig- we also evaluated MurA, an enolpyruvoyl transferase
that converts UDP-GlcNAc to the corresponding C3 en-ure 4). Although the compounds contain a potentially
reactive ,-unsaturated carbonyl motif, these results olpyruvate derivative, and PBP1b, a prokaryotic enzyme
that forms the glycan chains of peptidoglycan [40]. Theshow that inhibition does not involve covalent modifica-
tion of the enzyme. The structural similarities between substrate for PBP1b is the undecaprenyl-diphosphoryl-
disaccharide donor, Lipid II. Thus, MurA uses UDP-the inhibitors evidently reflect the fact that they bind to
the same region of the enzyme. The limited structural GlcNAc but is not a Gtf, whereas PBP1b is a Gtf that uses
a diphospholipid rather than a diphosphonucleoside asdiversity of the hits should simplify the analysis of struc-
ture-activity relationships. a leaving group.
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Figure 3. Selected MurG Inhibitors
Structures of selected compounds that caused40% MurG inhibition at a concentration of 2.5 g/ml (5 M). Four conserved core structures
are indicated. The C-C double bond geometries have not been experimentally established. All compounds were from commercially available
ChemDiv libraries. Assay conditions are provided in Experimental Procedures.
Each of the compounds shown in Table 2 was screened the structures in the PDB database shows that the con-
formations of UDP-hexose substrates bound to en-for its ability to inhibit the panel of enzymes. The com-
pounds were tested in duplicate or in triplicate at three zymes can vary significantly (Figure 5A). The variations
occur largely around the diphosphate linkage, which hasdifferent concentrations, ranging from 5 M to 100 M.
For solubility reasons, higher concentrations were not shallow rotational barriers and the ability to adopt a
large number of isoenergetic conformations. Thus, theevaluated. Up to the highest concentrations tested,
none of the compounds inhibited OGT, MurA, or PBP1b. nucleoside and hexose portions of the substrate can be
presented in very different orientations depending onSince the first two of these enzymes utilize UDP-GlcNAc
substrates, these results show that it is possible to the enzyme, reflecting large differences in the substrate
binding pockets. Inhibitors that are relatively rigid, asscreen for displacement of UDP-GlcNAc from one en-
zyme without selecting for compounds that bind to all are most of our hit compounds, would not be expected
to bind equivalently to enzymes with such differentlyUDP-GlcNAc processing enzymes. An examination of
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Figure 4. Kinetic Characterization of Selected MurG Inhibitors
Double reciprocal plots for the MurG reaction with UDP-GlcNAc as the variable substrate in the presence of inhibitors 1 (A), 5 (B), and 7 (C).
Conditions for the colorimetric (A and C) and radiometric (B) assays are described in Experimental Procedures.
(A) 0 (), 1 (), and 2 M () compound 1 at a fixed concentration of C20 Lipid I (60 M) with the concentration of UDP-GlcNAc varied from
40–700 M.
(B) 0 (), 1 (), and 2 M () compound 5 at a fixed concentration of C10 Lipid I (20 M) with the concentration of UDP-GlcNAc varied from
7–210 M.
(C) 0 (), 3 (), and 4.5 M () compound 7 at a fixed concentration of C20 Lipid I (60 M) with the concentration of UDP-GlcNAc varied from
40–700 M.
shaped active sites even if they utilize the same sub- for the design of selective Gtf inhibitors. We initially
considered using a kinetic assay to screen MurG forstrate.
We did find that some of the MurG inhibitors also compounds that inhibit enzymatic activity. Although we
have devised both radiometric and colorimetric assaysinhibit GtfB, a glycosyltransferase that is known to have
a donor binding site very similar to that of MurG (Figure to monitor MurG activity [5, 7], we decided against using
a kinetic assay screening for several reasons. One rea-5B). Given the similarities in the glycosyl donor binding
domains, it may not be surprising that some of the inhibi- son is that we obtain the Lipid I substrate analogs used
in the kinetic assays by chemical synthesis [4, 5], andtors inhibit GtfB. However, it is still possible to achieve
remarkable selectivity. For example, compound 5, a we did not relish the idea of using large amounts of
this compound in a random screen. In addition, kineticcompetitive inhibitor of MurG with respect to UDP-
GlcNAc, is selective for MurG by a factor of at least 30. assays also require precise timing and can be techni-
cally demanding, particularly if they involve the use ofAlthough MurG and GtfB have very similar folds, their
amino acid compositions are different, and there are secondary enzymes to detect product, as does our col-
orimetric assay [7]. Assays involving secondary en-many differences in the details of the donor binding
sites. Based both on our experimental results and struc- zymes are also subject to false positives related to inhi-
bition of the read-out enzymes. Finally, many of thetural considerations, we think that glycosyl donor dis-
placement screens show great promise for the identifi- compounds found in libraries are relatively nonpolar and
form micellar aggregates at low concentrations, andcation of selective Gtf inhibitors. Furthermore, we think
that identifying and optimizing the features that provide kinetic assays are highly sensitive to inhibition by these
aggregates [31].for discrimination will substantially improve the selectiv-
ity of our initial hits. We felt that a donor displacement assay offered sev-
eral potential advantages over a kinetic assay, including
technical simplicity and reduced sensitivity to artifactsDiscussion
related to compound aggregation. In addition, we hoped
that a majority of hits would be competitive inhibitorsGlycosyltransferases play many roles in cells, most of
which are poorly understood. For example, NDP-Gtfs in with respect to UDP-GlcNAc and would thus fall into a
limited number of structural classes. In contrast, a ki-the endoplasmic reticulum and the Golgi apparatus are
known to be involved in the assembly of the oligosac- netic screen of a two-substrate enzyme such as MurG
could yield inhibitors that operate by several mecha-charides that are presented on glycoproteins and glyco-
lipids [41–43]. These glycoproteins and glycolipids me- nisms. False positives related to compound aggregation
may further increase the numbers of different types ofdiate a variety of cell-cell recognition events, and it is
known from mutational studies and knockout experi- inhibitors identified in a kinetic screen, making it difficult
to analyze the hits to design better compounds. As wements that alterations in the patterns of glycosylation
can be pathogenic. However, it has been difficult to have reported above, the hits identified in the donor
displacement assay fall into a small number of catego-probe the roles of individual glycosyltransferases or their
products because, with few exceptions, selective glyco- ries, and this should simplify structural analysis.
Although we perceived several advantages of a do-syltransferase inhibitors do not exist. Because such
compounds would be useful for a variety of purposes, nor-based displacement assay for screening, the single
most important reason for exploring the strategy is thatthere is great interest in strategies to make Gtf inhibitors.
We began to explore strategies for the high-throughput it can potentially be extended to other NDP-Gtfs. A
handful of crystal structures of Gtfs are now available,screening of Gtfs in order to identify good starting points
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Table 2. IC50 of Inhibitors against Selected Enzymes
IC50 (M)
Compounds MurG OGT MurA PBP1b GtfB
1.4 100a 100a 100a 20
3.4 100 100 100 4
3.5 100 100 100 15
6.4 100 100 100 11
1.4 100 100 100 50
4.0 100 100 100 100
5.4 100 100 100 50
a No inhibition was observed, but this compound aggregates at high concentrations.
and sequence analysis reveals that thousands of other two of which are Gtfs that are either known (GtfB) or
proposed (OGT) to be structurally related to MurG. LikeGtfs are structurally related to these enzymes [14].
Therefore, it is possible to predict, using a combination MurG, these enzymes are inverting Gtfs that form
-glycosides from -linked UDP-GlcNAc (OGT) or UDP-of structural data and sequence information, where a
glycosyl donor might be labeled with a fluorescent tag glucose (GtfB) donors. The results show that the com-
pounds identified using the donor displacement assayto enable a displacement assay. Whether it is worth
screening other Gtfs using such a strategy, however, are indeed selective for MurG over these other NDP-
Gtfs as well as other enzymes that utilize UDP-GlcNAcdepends on whether results of the MurG screen appear
promising. The donor substrate used by MurG, UDP- as a substrate (MurA). These findings bode well for the
utility of donor-based displacement assays for high-GlcNAc, is a substrate for many enzymes in both pro-
karyotic and eukaryotic cells. Furthermore, a majority throughput screening of Gtfs.
We are attempting to obtain cocomplexes of MurGof the 7000 known and putative Gtfs use UDP or TDP
sugar donors. Therefore, it was essential to assess whether with various inhibitors bound in order to understand the
mode of binding in detail. Combined with the screeningcompounds identified via high-throughput screening of
MurG could inhibit other enzymes that use similar or data on the hit compounds, this information should
make it possible to prepare focused libraries of com-identical substrates. We examined four other enzymes,
Identification of Selective Inhibitors for MurG
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Figure 5. Substrate and Active-Site Geometries for Different UDP-GlcNAc Processing Enzymes
(A) Overlay of UDP-GlcNAc from the MurG:UPD-GlcNAc complex (red) and from the MurA:UDP-GlcNAc complex (green) showing different
conformations.
(B) Overlay of the donor binding site of MurG (light blue) with the corresponding binding site of GtfB (green). The sulfate ion (red) in GtfB is
superimposed with the -phosphate of UDP-GlcNAc (dark blue) in MurG.
tration of 25 g/ml in a final volume of 20 l. About 64,000 com-pounds to identify better inhibitors. Additionally, we are
pounds were screened in duplicate at the Institute of Chemistry andexploring the utility of the donor-displacement assay
Cell Biology, a collaborative screening facility located at Harvarddescribed here to screen other UDP-sugar transferases.
Medical School. The compounds screened were from a variety of
different libraries, including Bionet, Maybridge, Peakdale, ChemDiv
Significance Combilab and International collections, the NCI Structural Diversity
Set, NINDS Custom Collection, and the ICCB Discretes Collections
2, 3, and 4 (a series of compounds synthesized by ICCB chemists),Glycosyltransferases play key roles in all organisms.
the dihydropyrancarboxamide diversity oriented syntesis (DOS) set,Understanding these roles requires the ability to ma-
and the ICCB DOS set 1 (a set of compounds from a variety of DOS
nipulate individual glycosyltransferases. Selective gly- libraries).
cosyltransferase inhibitors would be valuable tools for
probing the functions of glycosyltransferases and their Kinetic Assay Used for Secondary Screening
of MurG Inhibitorsproducts. With few exceptions, however, selective gly-
Assays were carried out by incubating inhibitors at a final concentra-cosyltransferase inhibitors do not exist. Furthermore,
tion of 2.5 g/ml (5 M) with 14 M UDP-14C-GlcNAc and 15 Mit is not yet clear how one might proceed in developing
C20 Lipid I analog [44] in 10 l MurG reaction buffer (50 mM HEPESsuch inhibitors. We are exploring the utility of a high- [pH 7.9], 5 mM MgCl2). Reactions were started by adding 0.5 l of
throughput screen based upon displacement of a fluo- 0.01 mg/ml MurG stock (in 20 mM Tris, [pH 7.9], 150 mM NaCl, and
rescent glycosyl donor to discover inhibitors for a pro- 50 mM EDTA) to the substrate solution and were quenched after 2
min by adding 10 l 0.1% SDS and chilling on ice. Products andtotypical glycosyltransferase, E. coli MurG. This donor
starting material were separated by cellulose chromatography (3MMdisplacement assay enables us to screen large num-
Whatman chromatography paper) in isobutyric acid: 1N NH4OH bers of compounds rapidly, and we have shown here
5:3 and quantitated by scintillation counting.that several compounds identified from a donor dis-
placement screen of MurG are selective for MurG over IC50 Measurements
closely related enzymes that use similar or identical IC50 measurements for MurG were carried out using the same assay
conditions as above, except that inhibitor concentration was variedsubstrates. The high-throughput screening strategy
from 0.5 M to 20 M. Data were fit using Prism to the equationdescribed here can be adapted to screen other Gtfs
and represents a general strategy to identify selective
Y  Ymin 
Ymax 	 Ymin
1  10(X-log IC50 )*h
,small molecule inhibitors of Gtfs that can be used to
probe glycosylation pathways.
where X is the logarithm of the inhibitor concentration, Y is the
reaction rate, and h is the Hill slope.Experimental Procedures
High-Throughput Screening Inhibition Kinetics
Compounds 1 and 7 were subjected to more detailed kinetic analysisThe high-throughput screens were carried in 384-well plates. A solu-
tion containing 50 mM HEPES (pH 8.0), 0.33 M compound 1, and using a fluorescence-based assay described previously [7]. In this
assay, the formation of UDP is coupled enzymatically to the oxida-2.6 M MurG was added to the wells. Each plate contained two
control wells, one with MurG and 1 alone and the other with MurG, tion of NADH. Briefly, reactions were carried out in 384-well mi-
croplates, and the decrease in NADH fluorescence was monitored1, and 25 M UDP. Under the assay conditions, the well containing
UDP gave a polarization reading that was approximately 50% that at 465 nm using a Perkin-Elmer HTS 700 Plus Bio-Assay Plate
Reader. Each reaction contained MurG reaction buffer (50 mMof the wells containing only MurG and 1. Test compounds were
added in 100 nl of DMSO to the sample wells to give a final concen- HEPES [pH 7.9], 5 mM MgCl2), 0.5 mM phospho(enol)pyruvate (PEP),
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0.2 U/l lactic dehydrogenase, 3 U/l pyruvate kinase (added as 10 using a gradient of 0%–45% acetonitrile in water/0.1% TFA over 15
min, at a flow rate of 1 ml per minute. Product formation was moni-U/l stock solution in 100 mM K2HPO4 [pH 7.6]), 0.25 mM NADH,
60 M C20 Lipid I analog, an appropriate amount of UDP-GlcNAc, tored by UV absorbance at 285 nM. Estimated IC50 values for GtfB
were determined based on the inhibition observed at 0 M, 5 M,ranging from 40–700 M, and 1 l enzyme 100-fold diluted from a
10 mg/ml stock (in 20 mM Tris [pH 7.9], 150 mM NaCl, and 50 mM 15 M, and 100 M (see Supplemental Data).
EDTA). Reaction volumes were 30 l. All of the components except
for the MurG substrates and MurG were premixed in a reservoir and Assay for OGT
dispensed into each well. The substrates were then added and the The mitochondrial splice variant of OGT, minus the first 50 amino
reaction mixtures were incubated for 5 min until a stable background acids, was cloned into pET 32b and expressed from Novagen BL21
rate was achieved. MurG was then added and the fluorescence (DE3) cells essentially as described [48]. The cell pellet was lysed
was monitored for 5–10 min. A time course for each reaction was with B-PER (Pierce) and rLysozyme (Novagen), and the soluble frac-
obtained. The initial rates were determined by calculating the slopes tion was purified using His-Bind Resin (Novagen) [48]. Reactions
(linear fitting) of the initial linear portion of the reaction time course were performed in buffer containing 10 mM Tris (pH 7.4) with 100
curves using KaleidaGraph (Synergy Software). Inhibition studies g /ml BSA. The peptide substrate (KKKYPGGSTPVSSANMM) was
were carried out in duplicate at two different concentrations of the used at 1 mM concentration. 14C UDP-GlcNAc (300 mCi/mmole spe-
inhibitors (1, 7). The Ki was calculated from the replots of the double cific activity) was added to a final concentration of 11 M. Inhibitors
reciprocal curves using the following equation for competitive inhi- tested were added in 0.5 l of DMSO (at final concentrations of 15
bition: and 100 M), and the final reaction volume was 20 l. The reactions
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. acid and spotted onto phosphocellulose (Whatman P81) paper
disks. The disks were washed for 3 
 5 min with 1% phosphoric
acid, 1 min with acetone, and dried before counting. Product forma-Compound 5 interferes with the NADH fluorescence and cannot be
tion was measured by liquid scintillation counting.studied using this assay. The inhibition pattern of this compound
was determined using the radiometric kinetic assay decribed above.
Supplemental Data
Supplemental data are available at http://www.chembiol.com/cgi/Assay for MurA
content/full/11/5/703/DC1.MurA was purified followed the procedure descried by McCoy et
al. [45]. Cells were grown at 37C to OD600 (60 ml LB) and induced
with IPTG for another 6 hr. Cells were harvested and resuspended Received: December 31, 2003
in 1.5 ml of 50 mM Tris (pH 7.5), 2 mM dithiothreitol (DTT), and Revised: February 17, 2004
sonicated. Cell debris was removed from the samples by centrifuga- Accepted: February 24, 2004
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